Ka ten kura pa duensa di Alzheimer, mas ten txeu opson di tratamentu pa djuda kontrola sintomas y frena avansu di duensa.
Alguns di kes tratamentu é:
1. Medikamentu: Ten txeu medikamentu ki ta djuda kontrola sintomas di duénsa di Alzheimer.
Kes inibidor di kolinesterasi sima donepezilu, rivastigmina i galantamina, ta djuda midjora funson kognitivu i mimória.
Memantina é un otu medikamentu ki podi djuda ku funson kognitivu y sintomas di konportamentu.
Modi ki bu ta vive: Faze izersísiu fíziku sénpri, kume kumida dretu i mante bons amizadi ku otus algen pode djuda algen ku Alzheimer fika más saúdi.
3. Terapias di konhisimentu y konportamentu: Terapias di konhisimentu, sima terapia di estimulason di konhisimentu, podi djuda midjora funson di konhisimentu y memória na pesoas ku duénsa di Alzheimer.
Terapias konportamental, sima terapia konportamental kognitivu, podi djuda kontrola sintomas konportamental y midjora kualidadi di vida.
4. Kuidadus: Kes algen ki ten duénsa di Alzheimer pode resebe kuidadus sima otus tipu di tratamentu.
5. Insaiu klíniku: Partisipa na insaiu klíniku di novus tratamentu pode djuda algen ten más saúdi i midjór tratamentu pa duénsa di Alzheimer.
É inportanti trabadja djuntu ku prestador di kuidadu di saúdi pa dizenvolve un planu di tratamentu individualizadu pa duénsa di Alzheimer, pamodi nisisidadi y sintómas di kada algen pode varia.
Tanbê, é inportanti djuda kel algen ku duénsa di Alzheimer i kes algen ki ta kuida di es.
Kumar A, Singh A, Aggarwal A: Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview. Indian J Exp Biol. 2017, 55 (2): 63-73.
Sutor B, Rasmussen KG: Electroconvulsive therapy for agitation in Alzheimer disease: a case series. J ECT. 2008, 24 (3): 239-41.
Boada M, Ramos-Fernández E, Guivernau B, Muñoz FJ, Costa M, Ortiz AM, Jorquera JI, Núñez L, Torres M, Páez A: Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Neurologia. 2016, 31 (7): 473-81.
Golde TE: The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005, 15 (1): 84-7.
Giacobini E: Therapy of Alzheimer disease: symptomatic or neuroprotective? J Neural Transm Suppl. 1994, 43 (): 211-7.
Haussmann R, Donix M: [Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia]. Nervenarzt. 2017, 88 (1): 40-45.
['Diskrison: médiku']
['Es site é sô pa studa i pa da informason.']
['Kes informason li ka debe uzadu pa faze diagnóstiku ô pa kura algun prubléma di saúdi.']
['Pur favor, toma nota ma redi neuronal ki ta jenera respóstas pa perguntas, é spesialmenti inakuradu óras ki ta papiadu di konteúdu numériku. Pur izénplu, nunbru di pesoas diagnostikadu ku un duénsa spesifiku.']
['Sénpri buska konsedju di bu médiku ó otu prestador di kuidadu di saúdi kualifikadu sobri un kondison médiku. Nunka ka bu nega konsedju di médiku profisional ô atrasa na buska-l pamodi algun kuza ki bu lé na es pájina. Si bu atxa ma bu pode ten un imerjénsia médiku, txoma 911 ô bai pa kuartu di imerjénsia más pértu imediatamenti.']
['Diskubri autor']
['Lei di Direitus Umanu Digital di 1998, 17 U.S.C. § 512 (o DMCA) ta dispunibiliza rikursus pa titular di direitus ki ta atxa ma material ki ta parsi na Internet ta viola ses direitus di akordu ku lei di direitus di autor di Stadus Unidus. ']
['Si bu kré, di bon fé, ki kualker kontiudu ô material disponibilizadu na nos site ô servisus ta viola bu direitus di autor, bo (ô bu ajenti) podi manda-nu un avizu ta pidi pa retiradu ô blokia es konteúdu ô material.']
['Nu ten ki manda un mensaji pa email (odja "Contact" pa kel email).']
['Es lei ta iziji ki bu notifikason di alegadu violason di copyright inklui kes siginti informason: (1) un deskripson di obra protejedu pa copyright ki e sujetu di alegadu violason; (2) un deskripson di kel konteúdu alegadu y informason sufisienti pa permiti-nu lokaliza kel konteúdu; (3) informason di kontatu pa bo, inkluindu bu enderesu, númeru di tilifon i enderesu di email; (4) un deklarason di bo ki ten un bon fé ma kel konteúdu di forma reklamadu ka e autorizadu pa donu di copyright, o pa se ajenti, o pa kualker lei; ']
['5. un deklarason di bu senhoriu, asinadu sob pena di perjúriu, ma informason na notifikason é izatu y ma bu ten autoridadi pa pratika kel direitu di autor ki foi violadu;']
['i (6) un asinatura fíziku ô iletróniku di kel algen ki é donu di direitus di autor ô di un algen ki sta autorizadu pa aji na se nómi.']
['Si bu ka da tudu informason, kel informason pode dimora txeu ténpu.']
['Kontaktu di Grupu']
['Pur favor, manda-nu email ku kalker pergunta/sugeston.']
How to treat alzheimer?
There is no cure for Alzheimer's disease, but there are several treatment options available to help manage the symptoms and slow the progression of the disease.
Some of these treatments include:
1. Medications: There are several medications available that can help manage the symptoms of Alzheimer's disease.
These include cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, which can help improve cognitive function and memory.
Memantine is another medication that can help with cognitive function and behavioral symptoms.
2. Lifestyle changes: Engaging in regular physical exercise, eating a healthy diet, and maintaining social connections can help improve overall health and well-being for people with Alzheimer's disease.
3. Cognitive and behavioral therapies: Cognitive therapies, such as cognitive stimulation therapy, can help improve cognitive function and memory in people with Alzheimer's disease.
Behavioral therapies, such as cognitive behavioral therapy, can help manage behavioral symptoms and improve quality of life.
4. Supportive care: Supportive care, such as occupational therapy, speech therapy, and physical therapy, can help people with Alzheimer's disease maintain their independence and function as long as possible.
5. Clinical trials: Participating in clinical trials for new treatments and therapies can provide access to cutting-edge treatments and help contribute to the development of new treatments for Alzheimer's disease.
It is important to work closely with a healthcare provider to develop an individualized treatment plan for Alzheimer's disease, as the needs and symptoms of each person can vary.
Additionally, it is essential to provide emotional support and care for both the person with Alzheimer's disease and their caregivers.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na kel ténpu']
['BioMedLib ta uza konputador automatizadu (algoritmus di aprendizagen di mákina) pa gera pares di pergunta y rasposta.']
['Nu ta kumesa ku 35 milhon di publikason biomédicu di PubMed/Medline. tanbê pájinas di internet di RefinedWeb.']
